Novo Nordisk A/S (NVO)
36.53
-0.55
(-1.48%)
USD |
NYSE |
Mar 20, 16:00
36.56
+0.03
(+0.08%)
After-Hours: 20:00
Novo Nordisk Research and Development Expense (Quarterly) : 2.283B for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Evaxion AS | 2.558M |
| Ascendis Pharma A/S | 88.09M |
| Viking Therapeutics, Inc. | 153.46M |
| DBV Technologies SA | 26.82M |
| Cellectis SA | 24.42M |